InSphero AG has signed a definitive agreement to acquire DOPPL SA, a Lausanne-based innovator in organoid technologies, including the Sun Bioscience Gri3D® platform. The deal strengthens InSphero’s position as the most comprehensive provider of advanced 3D in vitro models for drug discovery and safety testing.
The Physicians Committee and InSphero Launch Award Program to Accelerate Adoption of Human In Vitro Models.
InSphero appoints former Evotec CEO Dr. Werner Lanthaler to its Board of Directors, strengthening its mission to scale reliable 3D in vitro drug testing solutions.
InSphero announced a new collaborative partnership with Hesperos, uniting two leading innovators in the field of advanced in vitro and microphysiological (MPS) systems.
InSphero announced a new collaborative partnership with Hesperos, uniting two leading innovators in the field of advanced in vitro and microphysiological (MPS) systems.
InSphero has entered into a distribution agreement with Tessara Therapeutics, an Australian biotech company known for its advanced neuronal microtissue technology. This agreement further strengthens our portfolio of physiologically relevant 3D models and enables us to offer best-in-class neuronal assays to our global customer base.
InSphero is proud to announce that Chief Scientific Officer, Dr. Madhu Nag, has been appointed as a member of the Society for Laboratory Automation and Screening (SLAS) Board of Directors, serving a three-year term starting January 1, 2025. Dr. Nag will also take on the role of Board Secretary.
InSphero, the global leader in scalable and reliable 3D in vitro cell culture solutions for drug discovery, takes a leading role in the recently awarded Chips JU European UNLOOC Project to advance its technology platform and address diversity in drug efficacy and safety testing.
InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. FDA's NCTR have published the largest-ever benchmarking study on liver toxicity using 3D InSight™ Human Liver Microtissues.
InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. FDA's NCTR have published the largest-ever benchmarking study on liver toxicity using 3D InSight™ Human Liver Microtissues.
InSphero, a leading innovator in 3D Cell Culture and Organ-on-Chip technology, has announced a new collaboration with Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, and the Université Libre de Bruxelles (ULB) Center for Diabetes Research.
InSphero AG is pleased to announce its exclusive commercialization of TrueCardium® Cardiac Organoid Platform in partnership with Genome Biologics.
Fill in form below to contact our 3D in vitro experts
Get the latest news on 3D in vitro research
Fill in the form below to view this resource